Chronic neuroblastoma - Indolent stage 4 disease in children

被引:22
|
作者
Kushner, BH [1 ]
Kramer, K [1 ]
Cheung, NKV [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA
关键词
neuroblastoma; chronic disease; indolent disease; biologic therapy; chemotherapy;
D O I
10.1002/cncr.10800
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. An indolent course is associated with neuroblastoma (NB) in adolescents and adults. In the current study, the authors analyzed this phenomenon in a large series of children with metastatic NB. METHODS. The authors studied 38 patients who were diagnosed with NB in the first decade of life and had metastatic disease 5 years or more from diagnosis. RESULTS. The median age at diagnosis was 3 years 10 months. MYCN was amplified in 2 of 28 patients tested. Of 30 patients with classic Stage 4 NB, 9 had a late first recurrence of disease (4.3-13 years from diagnosis). Of eight patients who had atypical cases at diagnosis (one isolated mandibular lesion, two Stage 4-N, five non-Stage 4), six had a late first distant recurrence of disease (4 years 11 months-38 years 8 months). Nineteen patients were off therapy continuously for 3 years or more before disease recurred a first or second time. Myeloablative therapy was used to consolidate a first or second response in 27 patients. High-dose conventional therapy helped to achieve a second remission of disease in 9 of 20 patients assessable for response of first recurrence but achieved no major responses of second or third relapse in 10 of 11. patients. The combination of anti-G(D2) immunotherapy and/or cis-retinoic acid, targeted radiotherapy, and multiple cycles of chemotherapy with modest toxicity helped prolong survival. Twelve patients survive at 5 years 6 months+ to 19 years 4 months+ from diagnosis (median, 6 years 10 months+), including four with complete remission of disease; 10 received anti-GD2 immunotherapy after recurrence. The other 26 patients died of disease (n = 22) or toxicity (n = 4) at 5 years-41 years 5 months from diagnosis (median, 6 years 5 months). CONCLUSIONS. The concept of indolent or smoldering NB should not be limited to adolescents/adults. The expanding repertoire of anti-NB treatments, including biologic therapies and chemotherapy regimens of modest toxicity, can convert childhood NB into a chronic disease with prolonged survival after recurrence. (C) 2001 American Cancer Society.
引用
收藏
页码:1366 / 1375
页数:10
相关论文
共 50 条
  • [1] Ganglioneuroblastoma stage 4: An indolent course of disease
    van Noesel, Max
    de Jong, Remco
    Geneuglijk, Jaap
    Tamminga, Rienk
    PEDIATRIC BLOOD & CANCER, 2007, 49 (04) : 476 - 476
  • [2] Survival and Late Effects in Children With Stage 4 Neuroblastoma
    Perwein, Thomas
    Lackner, Herwig
    Sovinz, Petra
    Benesch, Martin
    Schmidt, Sandrin
    Schwinger, Wolfgang
    Urban, Christian
    PEDIATRIC BLOOD & CANCER, 2011, 57 (04) : 629 - 635
  • [3] Bone marrow relapse in stage 4 neuroblastoma of children in Shanghai
    Li, Hong
    Zhao, Jie
    Yang, Jingwei
    Tang, Jingyan
    Zhang, Ting
    Jiang, Hui
    Shao, Jingbo
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (01): : 145 - 154
  • [4] Brain metastasis in children with stage 4 neuroblastoma after multidisciplinary treatment
    Zhu, Jia
    Wang, Juan
    Zhen, Zi-Jun
    Lu, Su-Ying
    Zhang, Fei
    Sun, Fei-Fei
    Li, Peng-Fei
    Huang, Jun-Ting
    Cai, Rui-Qing
    Sun, Xiao-Fei
    CHINESE JOURNAL OF CANCER, 2015, 34
  • [5] Brain metastasis in children with stage 4 neuroblastoma after multidisciplinary treatment
    Jia Zhu
    Juan Wang
    Zi-Jun Zhen
    Su-Ying Lu
    Fei Zhang
    Fei-Fei Sun
    Peng-Fei Li
    Jun-Ting Huang
    Rui-Qing Cai
    Xiao-Fei Sun
    Chinese Journal of Cancer, 2015, 34 (11) : 531 - 537
  • [6] The Plasma Catecholamine Detection in Diagnosis and Treatment of Stage 4 Neuroblastoma in Children
    Xiong, X.
    Peng, X.
    Li, C.
    Feng, C.
    Wu, P.
    Yang, L.
    Weng, W.
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S336 - S336
  • [7] Brain Metastasis in Children with Stage 4 Neuroblastoma: Risk Factors and Characteristics
    Elbaz, M.
    Said, A. B. A.
    Dounia, B.
    Elhoudzi, J.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S605 - S605
  • [8] A strike against indolent neuroblastoma
    Cook, April
    Bernstein, Emily
    EBIOMEDICINE, 2020, 60
  • [9] CIRCULATING IMMUNE-COMPLEXES IN SERA OF CHILDREN WITH NEUROBLASTOMA - CORRELATION WITH STAGE OF DISEASE
    BRANDEIS, WE
    HELSON, L
    WANG, Y
    GOOD, RA
    DAY, NK
    JOURNAL OF CLINICAL INVESTIGATION, 1978, 62 (06): : 1201 - 1209
  • [10] OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age
    Tweddle, DA
    Pinkerton, CR
    Lewis, IJ
    Ellershaw, C
    Cole, M
    Pearson, ADJ
    MEDICAL AND PEDIATRIC ONCOLOGY, 2001, 36 (01): : 239 - 242